OBJECTIVES:Neonates undergoing complex congenital heart surgery have a significant incidence of neurologic problems. Erythropoietin has antiapoptotic, antiexcitatory, and anti-inflammatory properties to prevent neuronal cell death in animal models, and improves neurodevelopmental outcomes in full-term neonates with hypoxic ischemic encephalopathy. We designed a prospective phase I/II trial of erythropoietin neuroprotection in neonatal cardiac surgery to assess safety and indicate efficacy. METHODS:Neonates undergoing surgery for D-transposition of the great vessels, hypoplastic left heart syndrome, or aortic arch reconstruction were randomized to 3 perioperative doses of erythropoietin or placebo. Neurodevelopmental testing using the Bayley Scales of Infant and Toddler Development III was performed at age 12 months. RESULTS:Fifty-nine patients received the study drug. Safety profile, including magnetic resonance imaging brain injury, clinical events, and death, was not different between groups. Three patients in each group died. Forty-two patients (22 in the erythropoietin group and 20 in the placebo group; 79% of survivors) returned for 12-month follow-up. In the group receiving erythropoietin, mean Cognitive Scale scores were 101.1 ± 13.6, Language Scale scores were 88.5 ± 12.8, and Motor Scale scores were 89.9 ± 12.3. In the group receiving placebo, Cognitive Scale scores were 106.3 ± 10.8 (P = .19), Language Scores were 92.4 ± 12.4 (P = .33), and Motor Scale scores were 92.6 ± 14.1 (P = .51). CONCLUSIONS:Safety profile for erythropoietin administration was not different than placebo. Neurodevelopmental outcomes were not different between groups; however, this pilot study was not powered to definitively address this outcome. Lessons learned suggest optimized study design features for a larger prospective trial to definitively address the utility of erythropoietin for neuroprotection in this population.
RCT Entities:
OBJECTIVES: Neonates undergoing complex congenital heart surgery have a significant incidence of neurologic problems. Erythropoietin has antiapoptotic, antiexcitatory, and anti-inflammatory properties to prevent neuronal cell death in animal models, and improves neurodevelopmental outcomes in full-term neonates with hypoxic ischemicencephalopathy. We designed a prospective phase I/II trial of erythropoietin neuroprotection in neonatal cardiac surgery to assess safety and indicate efficacy. METHODS: Neonates undergoing surgery for D-transposition of the great vessels, hypoplastic left heart syndrome, or aortic arch reconstruction were randomized to 3 perioperative doses of erythropoietin or placebo. Neurodevelopmental testing using the Bayley Scales of Infant and Toddler Development III was performed at age 12 months. RESULTS: Fifty-nine patients received the study drug. Safety profile, including magnetic resonance imaging brain injury, clinical events, and death, was not different between groups. Three patients in each group died. Forty-two patients (22 in the erythropoietin group and 20 in the placebo group; 79% of survivors) returned for 12-month follow-up. In the group receiving erythropoietin, mean Cognitive Scale scores were 101.1 ± 13.6, Language Scale scores were 88.5 ± 12.8, and Motor Scale scores were 89.9 ± 12.3. In the group receiving placebo, Cognitive Scale scores were 106.3 ± 10.8 (P = .19), Language Scores were 92.4 ± 12.4 (P = .33), and Motor Scale scores were 92.6 ± 14.1 (P = .51). CONCLUSIONS: Safety profile for erythropoietin administration was not different than placebo. Neurodevelopmental outcomes were not different between groups; however, this pilot study was not powered to definitively address this outcome. Lessons learned suggest optimized study design features for a larger prospective trial to definitively address the utility of erythropoietin for neuroprotection in this population.
Authors: R R Clancy; S A McGaurn; J E Goin; D G Hirtz; W I Norwood; J W Gaynor; M L Jacobs; G Wernovsky; W T Mahle; J D Murphy; S C Nicolson; J M Steven; T L Spray Journal: Pediatrics Date: 2001-07 Impact factor: 7.124
Authors: E H Austin; H L Edmonds; S M Auden; V Seremet; G Niznik; A Sehic; M K Sowell; C D Cheppo; K M Corlett Journal: J Thorac Cardiovasc Surg Date: 1997-11 Impact factor: 5.209
Authors: Patrick S McQuillen; A James Barkovich; Shannon E G Hamrick; Marta Perez; Phil Ward; David V Glidden; Anthony Azakie; Tom Karl; Steven P Miller Journal: Stroke Date: 2007-02 Impact factor: 7.914
Authors: Richard A Jonas; David Wypij; Stephen J Roth; David C Bellinger; Karen J Visconti; Adre J du Plessis; Howard Goodkin; Peter C Laussen; David M Farrell; Jodi Bartlett; Ellen McGrath; Leonard J Rappaport; Emile A Bacha; Joseph M Forbess; Pedro J del Nido; John E Mayer; Jane W Newburger Journal: J Thorac Cardiovasc Surg Date: 2003-12 Impact factor: 5.209
Authors: David Wypij; Jane W Newburger; Leonard A Rappaport; Adre J duPlessis; Richard A Jonas; Gil Wernovsky; Ming Lin; David C Bellinger Journal: J Thorac Cardiovasc Surg Date: 2003-11 Impact factor: 5.209
Authors: Caroline C Menache; Adré J du Plessis; David L Wessel; Richard A Jonas; Jane W Newburger Journal: Ann Thorac Surg Date: 2002-06 Impact factor: 4.330
Authors: Joseph Atallah; Ari R Joffe; Charlene M T Robertson; Norma Leonard; Patricia M Blakley; Alberto Nettel-Aguirre; Reg S Sauve; David B Ross; Ivan M Rebeyka Journal: J Thorac Cardiovasc Surg Date: 2007-09 Impact factor: 5.209
Authors: Dean B Andropoulos; Hasan B Ahmad; Taha Haq; Ken Brady; Stephen A Stayer; Marcie R Meador; Jill V Hunter; Carlos Rivera; Robert G Voigt; Marie Turcich; Cathy Q He; Lara S Shekerdemian; Heather A Dickerson; Charles D Fraser; E Dean McKenzie; Jeffrey S Heinle; R Blaine Easley Journal: Paediatr Anaesth Date: 2014-03 Impact factor: 2.556
Authors: Jyrson Guilherme Klamt; Walter Villela de Andrade Vicente; Luis Vicente Garcia; Fabio Carmona; João Abrão; Antônio Carlos Menardi; Paulo Henrique Manso Journal: Braz J Cardiovasc Surg Date: 2017 Nov-Dec
Authors: Raymond Stegeman; Kaya D Lamur; Agnes van den Hoogen; Johannes M P J Breur; Floris Groenendaal; Nicolaas J G Jansen; Manon J N L Benders Journal: Front Neurol Date: 2018-07-03 Impact factor: 4.003
Authors: Darlene Huisenga; Sacha La Bastide-Van Gemert; Andrew Van Bergen; Jane Sweeney; Mijna Hadders-Algra Journal: Dev Med Child Neurol Date: 2020-03-09 Impact factor: 5.449